144650-00-0Relevant articles and documents
AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE
-
Page/Page column 144, (2009/10/06)
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain amino-ethyl-amino-aryl (AEAA) compounds which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.
CERTAIN AMINOMETHYL PHENYLIMIDAZOLE DERIVATIVES; AND 4-ARYL SUBSTITUTED PIPERAZINYL AND PIPERIDINYLMETHYL PHENYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF DOPAMINE RECEPTOR SUBTYPE LIGANDS
-
, (2008/06/13)
This invention encompasses compounds of the formulas: STR1 where R. sub.1 R 3, R 4, R 6, X, Y, and Z are T are variables; andM is STR2 where R 2 is a variable; or R. sub.1 and R. sub.2 together may represent--(CH 2) n1 where n 1 is 1, 2, or 3.P
2-Phenyl-4-(aminomethyl)imidazoles as Potential Antipsychotic Agents. Synthesis and Dopamine D2 Receptor Binding
Thurkauf, Andrew,Hutchison, Alan,Peterson, John,Cornfield, Linda,Meade, Robin,et al.
, p. 2251 - 2255 (2007/10/02)
A series of 2-phenyl-4-(aminomethyl)imidazoles were designed as conformationally restricted analogs of the dopamine D2 selective benzamide antipsychotics.The title compounds were synthesized and tested for blockade of YM-09151 binding in cloned African green monkey dopamine D2 receptor preparations.The binding affinity data thus obtained were compared against that of the benzamides and a previously described series of 2-phenyl-5-(aminomethyl)pyrroles.